Alembic Pharmaceuticals gains on completing ANVISA GMP audit at API-III Facility without any observations
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Alembic Pharmaceuticals is currently trading at Rs. 486.70, up by 2.25 points or 0.46% from its previous closing of Rs. 484.45 on the BSE.
The scrip opened at Rs. 483.10 and has touched a high and low of Rs. 490.00 and Rs. 479.35 respectively. So far 1534 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 792.30 on 28-Apr-2022 and a 52 week low of Rs. 475.00 on 17-Mar-2023.
Last one week high and low of the scrip stood at Rs. 499.85 and Rs. 476.70 respectively. The current market cap of the company is Rs. 9585.40 crore.
The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 17.75% and 12.64% respectively.
Alembic Pharmaceuticals has successfully completed the Brazilian Health Regulatory Agency (ANVISA) GMP audit at API-III Facility at Karakhadi without any observations for its 56 APIs. The inspection was conducted from March 20, 2023 to March 24, 2023.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
